Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2019 Earnings Results

Rhythm Pharmaceuticals Misses on EPS, Stock Down 0.5%

Rhythm Pharmaceuticals reported a loss of $1.24 per share, which was below expectations, though no revenue figures were disclosed. The stock reacted negatively, dropping 0.5%, likely due to the absence of guidance and clarity on future performance. Investors may be concerned about the company's path forward without clear financial targets.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.24	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook due to the lack of guidance. They emphasized their commitment to advancing clinical trials.

Management did not provide specific guidance for future quarters.

The company is focused on its ongoing clinical trials and product development.

Rhythm Pharmaceuticals Misses on EPS, Stock Down 0.5%

Key numbers

Management commentary

Rhythm Pharmaceuticals, Inc.

More earnings this week

Rhythm Pharmaceuticals Misses on EPS, Stock Down 0.5%

Key numbers

Management commentary